Ivabradine


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Chronic stable angina pectoris in coronary artery disease patients with normal sinus rhythm
Adult: Initially, should not exceed 5 mg bid. Increase if necessary to 7.5 mg bid after 3-4 wk. Titrate downward to as low as 2.5 mg bid, if patient develops bradycardia symptoms (e.g. dizziness, fatigue) or resting heart rate is persistently <50 beats/min.
Elderly: ≥75 yr Initiate treatment at 2.5 mg bid. Titrate up if necessary.

Oral
Chronic heart failure
Adult: Initially, 5 mg bid. After 2 wk, increase to 7.5 mg bid if resting heart rate is persistently >60 beats/min or decrease to 2.5 mg bid if resting heart rate is persistently <50 beats/min. If heart rate is between 50-60 beats/min, maintain 5 mg bid. Max: 7.5 mg bid.
Elderly: ≥75 yr Initiate treatment at 2.5 mg bid. Titrate up if necessary.
Renal Impairment
CrCl (mL/min Dosage
<15 Use w/ caution.
Hepatic Impairment
Severe: Contraindicated.
Cách dùng
Should be taken with food. Avoid excessive consumption of grapefruit juice.
Chống chỉ định
Resting heart rate <70 beats/min prior to treatment, cardiogenic shock, acute MI, severe hypotension (<90/50 mmHg), sick sinus syndrome, SA block, unstable or acute heart failure, pacemaker dependent, unstable angina, 3rd degree AV block. Severe hepatic impairment. Pregnancy and lactation. Concurrent use w/ potent CYP3A4 inhibitors (e.g. azole antifungals, macrolides, HIV protease inhibitors or nefazodone), moderate CYP3A4 inhibitors (e.g. verapamil or diltiazem).
Thận trọng
Patient w/ retinitis pigmentosa, 2nd degree AV block, congenital QT prolongation, AF or other cardiac arrhythmias that interfere w/ sinus node function. Severe renal impairment (CrCl <15 mL/min).
Phản ứng phụ
Luminous phenomena in the visual field (phosphenes), blurred vision, bradycardia, other cardiac arrhythmias, syncope, hypotension, asthenia, fatigue, headache, dizziness, nausea, constipation, diarrhoea, dyspnoea, muscle cramps, skin reactions, angioedema, hyperuricaemia, eosinophilia, elevated blood-creatinine concentrations.
MonitoringParameters
Monitor heart rate prior to initiation of treatment, prior to increasing dose or after decreasing dose; BP, cardiac rhythm.
Quá liều
Symptoms: Severe and prolonged bradycardia. Management: Treat severe bradycardia symptomatically. In case of bradycardia w/ poor haemodynamic tolerance, IV β-stimulating medicines e.g. isoprenaline may be used. If necessary, may institute temporary cardiac electrical pacing.
Tương tác
QT prolongation may be exacerbated by heart rate reduction w/ QT-prolonging drugs (e.g. quinidine, disopyramide, pimozide, ziprasidone). Concentration may be reduced w/ CYP3A4 inducers (e.g. rifampicin, barbiturates, phenytoin) and may require ivabradine dose adjustment.
Potentially Fatal: Increased serum concentration w/ potent CYP3A4 inhibitors (e.g. azole antifungals, macrolides, HIV protease inhibitors or nefazodone), moderate CYP3A4 inhibitors (e.g. verapamil or diltiazem).
Food Interaction
Food delays absorption but increases exposure by 20-30%. Increased serum concentration w/ grapefruit juice. Decreased serum concentration w/ St John's wort.
Tác dụng
Description: Ivabradine is a heart rate lowering agent that works through selective and specific inhibition of the cardiac pacemaker If current that controls the spontaneous diastolic depolarisation in the sinus node and regulates heart rate.
Pharmacokinetics:
Absorption: Almost completely absorbed from GI tract. Food delays absorption by approx 1 hr and increases exposure by 20-30%. Absolute bioavailability: Approx 40%. Time to peak plasma concentration: Approx 1 hr.
Distribution: Volume of distribution: Approx 100 L. Plasma protein binding: Approx 70%.
Metabolism: Extensively metabolised in the liver and gut via oxidation by CYP3A4 isoenzyme to form major active metabolite N-desmethyl-ivabradine (S-18982).
Excretion: Approx 4% as unchanged drug via urine; metabolites are excreted to a similar extent via urine and faeces. Plasma elimination half-life: 2 hr.
Đặc tính

Chemical Structure Image
Ivabradine

Source: National Center for Biotechnology Information. PubChem Database. Ivabradine, CID=132999, https://pubchem.ncbi.nlm.nih.gov/compound/Ivabradine (accessed on Jan. 21, 2020)

Bảo quản
Store at 25°C.
Phân loại MIMS
Phân loại ATC
C01EB17 - ivabradine ; Belongs to the class of other cardiac preparations.
References
Anon. Ivabradine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 23/11/2015.

Buckingham R (ed). Ivabradine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 23/11/2015.

Corlanor Film Coated Tablet (Amgen Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 23/11/2015.

FDA Approves Corlanor to Treat Heart Failure. U.S. FDA. https://www.fda.gov/. Accessed 23/11/2015.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Ivabradine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in